Welcome to our dedicated page for Surface Oncology news (Ticker: SURF), a resource for investors and traders seeking the latest updates and insights on Surface Oncology stock.
Surface Oncology, Inc. (NASDAQ: SURF) is a clinical-stage immuno-oncology company pioneering the development of next-generation cancer immunotherapies. Founded on cutting-edge research from world-renowned immunologists and cancer researchers from institutions like Memorial Sloan Kettering and Harvard, Surface Oncology aims to harness the power of the immune system to fight cancer more effectively.
The company's innovative pipeline is focused on the tumor microenvironment, featuring two wholly-owned antibody programs: SRF388 and SRF114. SRF388 targets IL-27, an immunosuppressive cytokine, and is currently in Phase 2 clinical trials. It has shown promise as both a monotherapy and in combination with checkpoint inhibitors, and has been granted Orphan Drug and Fast Track designations by the FDA for refractory hepatocellular carcinoma. SRF114, in Phase 1 trials, specifically depletes CCR8+ regulatory T cells within the tumor microenvironment, aiming to drive anti-tumor immunity.
Surface Oncology has also established significant partnerships with major pharmaceutical companies, including Novartis and GlaxoSmithKline, to advance additional pipeline programs. Their collaboration with Novartis targets CD73 (NZV930), currently in Phase 1, while their partnership with GlaxoSmithKline focuses on PVRIG (GSK4381562), also in Phase 1.
Recently, Surface Oncology completed a $35 million Series A financing round, bolstered by A-list investors such as Atlas Venture, New Enterprise Associates, Fidelity Biosciences, Lilly Ventures, Amgen Ventures, Novartis Institute for Biomedical Research, and former Bristol-Myers Squibb R&D head Elliott Sigal. The company has used these funds to advance its clinical programs and explore new therapeutic avenues.
In a significant development, Surface Oncology has announced a proposed merger with Coherus BioSciences. This merger aims to combine resources to advance SRF388 and SRF114 through clinical trials and eventually to market. The merger is expected to provide Surface with net cash of $20 million to $25 million at closing, although the outcome is contingent on shareholder approval.
Financially, Surface Oncology reported a net loss of $28.2 million for the second quarter of 2023. The company anticipates that its cash reserves will sustain operations through the end of 2023. Amidst these developments, Surface continues to focus on its core mission: to develop innovative, next-generation cancer treatments that offer meaningful and sustained anti-tumor responses.
Surface Oncology (Nasdaq: SURF) announced promising preclinical data for SRF114, a fully human anti-CCR8 antibody, presented at the AACR Annual Meeting 2023. The research shows that SRF114 induces a pro-inflammatory tumor microenvironment, enhancing anti-tumor activity in mouse models resistant to checkpoint inhibitors. Key findings demonstrate that SRF114 boosts CD8+ T cell expansion and pro-inflammatory cytokine production while selectively depleting CCR8+ regulatory T cells in tumors. This data strengthens the case for SRF114 as a potential best-in-class therapy and supports its Phase 1 clinical trial for advanced solid tumors. The poster presentation includes significant insights into SRF114's role in augmenting immune responses and improving survival in resistant melanoma models.
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology firm, will showcase preclinical data on SRF114, its anti-CCR8 antibody, at the AACR Annual Meeting 2023, scheduled for April 14-19, 2023, in Orlando, FL.
The poster, titled "Depletion of CCR8+ tumor Treg cells with SRF114 or anti-CCR8 therapy promotes robust antitumor activity and reshapes the tumor microenvironment toward a more pro-inflammatory milieu", will cover significant findings such as SRF114's ability to reduce tumor growth in murine models.
The session is set for April 18, 2023, from 1:30 p.m. to 5:00 p.m. ET.
Surface Oncology (Nasdaq: SURF) reported significant advancements in its clinical programs, focusing on SRF388 and SRF114, potential first-in-class therapies targeting IL-27 and CCR8, respectively. In Q4 2022, SRF388 demonstrated promising results in non-small cell lung cancer (NSCLC) trials, with confirmed partial responses in two patients. The company has extended its cash runway into Q3 2024, holding $124.8 million in cash as of December 31, 2022. Operating expenses increased, with R&D costs at $67 million for the year. Despite a net loss of $63.6 million for 2022, Surface remains optimistic, expecting updated clinical data in 2023 and initial SRF114 data in 2024.
Surface Oncology (Nasdaq: SURF), an immuno-oncology company, announced that its CEO, Rob Ross, M.D., will participate in a Novel Immuno-Oncology panel at the Cowen 43rd Annual Health Care Conference in Boston, MA, on March 6, 2023, at 9:10 a.m. ET. This session will focus on the company’s innovative therapies targeting the tumor microenvironment. A live audio webcast will be accessible on the Surface Oncology website, with a replay available afterward. The company is developing next-generation antibody therapies, including SRF388 and SRF114, and has collaborations with Novartis and GlaxoSmithKline.
Surface Oncology (Nasdaq: SURF) announced that CEO Rob Ross will participate in a fireside chat at the 2023 Guggenheim Oncology Days conference in New York City on February 9, 2023, at 1:35 p.m. ET. The session will be available via a live audio webcast, accessible on the company's Investors & Media section. Surface is focused on developing next-generation immunotherapies that target the tumor microenvironment, with programs including SRF388 and SRF114, targeting IL-27 and CCR8 respectively. Collaborations with Novartis and GlaxoSmithKline further bolster their pipeline. For more details, visit the Surface Oncology website.
Surface Oncology (SURF) announced the dosing of the first patient in its Phase 1/2 clinical study for SRF114, a novel anti-CCR8 antibody aimed at treating advanced solid tumors. The trial aims to evaluate SRF114's safety, tolerability, and efficacy, especially in patients with head and neck squamous cell carcinoma. Initial clinical data is expected in 2024. Pre-clinical studies indicate SRF114 effectively depletes CCR8+ Treg cells and reduces tumor growth, supporting its potential as a best-in-class treatment in immunotherapy.
Surface Oncology (Nasdaq: SURF) announced the presentation of new non-clinical data for SRF388 and SRF114 at the 2022 SITC Annual Meeting. Notable findings include that IL-27 correlates with PD-L1 expression in multiple cancers, suggesting potential for SRF388 to enhance immunotherapy effectiveness. Additionally, SRF114 demonstrated selective depletion of Treg cells, potentially inhibiting tumor growth. Both drugs are positioned for ongoing clinical studies, with SRF388 targeting IL-27's role in cancer immunity and SRF114 entering Phase 1 trials.
FAQ
What is the market cap of Surface Oncology (SURF)?
What does Surface Oncology, Inc. specialize in?
What are SRF388 and SRF114?
Who are some of the key scientific founders of Surface Oncology?
Which major pharmaceutical companies has Surface Oncology partnered with?
What recent financial achievements has Surface Oncology made?
What is the proposed merger between Surface Oncology and Coherus BioSciences?
What is Surface Oncology's financial outlook for 2023?
What are the designations received by SRF388?
What is the focus of Surface Oncology's pipeline?
What financial results did Surface Oncology report for Q2 2023?
